

# Vorapaxar in the Secondary Prevention of Atherothrombosis

New England Journal of Medicine

366, 1404-1413

DOI: [10.1056/nejmoa1200933](https://doi.org/10.1056/nejmoa1200933)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Human U1 small nuclear RNA pseudogenes do not map to the site of the U1 genes in 1p36 but are clustered in 1q12-q22.. Molecular and Cellular Biology, 1985, 5, 2172-2180.	1.1	42
2	Interaction of volkensin with HeLa cells: binding, uptake, intracellular localization, degradation and exocytosis. Cellular and Molecular Life Sciences, 2004, 61, 1975-1984.	2.4	50
3	Suppression of Arterial Thrombosis Without Affecting Hemostatic Parameters With a Cell-Penetrating PAR1 Pepducin. Circulation, 2012, 126, 83-91.	1.6	75
4	Recent Development in Thrombin Receptor Antagonist as Novel Antithrombotic Agent. Open Journal of Medicinal Chemistry, 2012, 02, 112-118.	0.7	1
5	Platelet protease-activated receptor antagonism in cardiovascular medicine. Coronary Artery Disease, 2012, 23, 375-379.	0.3	4
6	Risk of Intracranial Hemorrhage With Protease-Activated Receptor-1 Antagonists. Stroke, 2012, 43, 3189-3195.	1.0	21
7	Risk of Intracranial Hemorrhage With Protease-Activated Receptor-1 Antagonists. Stroke, 2012, 43, 3158-3159.	1.0	3
8	Secondary stroke prevention—personalized antiplatelet therapy. Nature Reviews Neurology, 2012, 8, 536-537.	4.9	3
9	Rapid P2Y <sub>12</sub> Inhibition. Circulation: Cardiovascular Interventions, 2012, 5, 328-331.	1.4	4
10	Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease. Future Cardiology, 2012, 8, 503-511.	0.5	5
11	Preventing Platelet Thrombosis With a PAR1 Pepducin. Circulation, 2012, 126, 13-15.	1.6	11
12	Antiplatelet and Antithrombin Strategies in Acute Coronary Syndrome: State-Of-The-Art Review. Current Cardiology Reviews, 2012, 8, 239-249.	0.6	16
13	Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. Journal of Thrombosis and Haemostasis, 2012, 10, 2006-2015.	1.9	40
14	Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood, 2012, 120, 5237-5246.	0.6	191
15	Beware of Novel Antiplatelet Therapy in Acute Coronary Syndrome Patients With Previous Stroke. Circulation, 2012, 125, 2821-2823.	1.6	24
16	Modern antiplatelet agents in coronary artery disease. Expert Review of Cardiovascular Therapy, 2012, 10, 1261-1272.	0.6	3
17	Bleeding and the Use of Antiplatelet Agents in the Management of Acute Coronary Syndromes and Atrial Fibrillation. Advances in Cardiology, 2012, 47, 125-140.	2.6	0
18	High-resolution crystal structure of human protease-activated receptor 1. Nature, 2012, 492, 387-392.	13.7	416

#	ARTICLE	IF	CITATIONS
19	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 <sup>Â</sup> P-TIMI 50 trial. <i>Lancet, The</i> , 2012, 380, 1317-1324.	6.3	202
20	Improving long-term outcome after myocardial infarction. <i>Lancet, The</i> , 2012, 380, 1290-1291.	6.3	0
21	Hot topics in cardiology: data from IABP-SHOCK II, TRILOGY-ACS, WOEST, ALTITUDE, FAME II and more. <i>Clinical Research in Cardiology</i> , 2012, 101, 861-874.	1.5	5
22	The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 762-770.	0.4	14
23	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American College of Cardiology (Chicago, Illinois, United States, March 24 <sup>â</sup> 27, 2012). <i>Revista Espanola De Cardiologia (English Ed )</i> , 2012, 65, 559.e1-559.e8.	0.4	0
25	The Year in Non <sup>â</sup> ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2127-2139.	1.2	13
26	Antiplatelet therapy in ischemic stroke: does one size fit all?. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1455-1457.	0.6	0
27	Vorapaxar's benefits exceed risks in select patients only. <i>Reactions Weekly</i> , 2012, &NA;, 1.	0.0	0
28	Resumen de los ensayos clÃnicos presentados en las Sesiones CientÃficas Anuales del American College of Cardiology (Chicago, Illinois, Estados Unidos, 24 <sup>â</sup> 27 de marzo de 2012). <i>Revista Espanola De Cardiologia</i> , 2012, 65, 559.e1-559.e8.	0.6	10
29	PAR-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombosis. <i>Handbook of Experimental Pharmacology</i> , 2012, , 239-260.	0.9	11
30	Newer Pharmaceutical Agents for STEMI Interventions. <i>Interventional Cardiology Clinics</i> , 2012, 1, 429-440.	0.2	0
31	Medical Management for Chronic Atherosclerotic Peripheral Arterial Disease. <i>Drugs</i> , 2012, 72, 2073-2085.	4.9	22
32	The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes. <i>Drugs</i> , 2012, 72, 2087-2116.	4.9	106
33	New Directions in Antiplatelet Therapy. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 433-445.	1.4	61
34	PAR-1 inhibitor antiplatelet agents: Performance below par?. <i>Indian Heart Journal</i> , 2012, 64, 594-597.	0.2	0
35	Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 319-336.	1.3	44
36	Vorapaxar beneficial in setting of prior MI, but not in patients who have experienced a stroke. <i>Nature Reviews Cardiology</i> , 2012, 9, 311-311.	6.1	0
39	Abdominal aortic aneurysm in patients affected by intermittent claudication: prevalence and clinical predictors. <i>BMC Surgery</i> , 2012, 12, S17.	0.6	28

#	ARTICLE	IF	CITATIONS
40	Endovascular treatment of lower extremity arteries is associated with an improved outcome in diabetic patients affected by intermittent claudication. BMC Surgery, 2012, 12, S19.	0.6	11
41	Ankle/brachial index to everyone. BMC Surgery, 2012, 12, S18.	0.6	10
42	The role of atherectomy in the treatment of lower extremity peripheral artery disease. BMC Surgery, 2012, 12, S13.	0.6	40
43	Platelets in the pathogenesis of vascular disease and their role as a therapeutic target. , 2011, , 201-226.		2
44	Vorapaxar expands antiplatelet options. Hamostaseologie, 2012, 32, 221-227.	0.9	8
45	Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. Journal of Thrombosis and Thrombolysis, 2012, 34, 36-43.	1.0	16
46	Harnessing the Platelet Signaling Network to Produce an Optimal Hemostatic Response. Hematology/Oncology Clinics of North America, 2013, 27, 381-409.	0.9	26
47	Emerging antithrombotic drugs for acute coronary syndrome. Expert Opinion on Emerging Drugs, 2013, 18, 307-318.	1.0	1
48	Platelet Biology and Receptor Pathways. Journal of Cardiovascular Translational Research, 2013, 6, 299-309.	1.1	64
49	Platelet Function Profiles in Patients with Diabetes Mellitus. Journal of Cardiovascular Translational Research, 2013, 6, 329-345.	1.1	46
50	Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18â€“19, 2012, Belo Horizonte, Minas Gerais, Brazil. Journal of Thrombosis and Thrombolysis, 2013, 36, 115-130.	1.0	0
51	Thrombin Receptor Antagonism in Antiplatelet Therapy. Cardiology and Therapy, 2013, 2, 57-68.	1.1	10
52	Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. Translational Research, 2013, 161, 421-429.	2.2	35
53	Basics of Antithrombotic Therapy for Cardiovascular Disease. Interventional Cardiology Clinics, 2013, 2, 499-513.	0.2	1
54	Investigational anticoagulants for hematological conditions: a new generation of therapies. Expert Opinion on Investigational Drugs, 2013, 22, 1281-1294.	1.9	8
55	Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: Challenging PLATO mortality rates. International Journal of Cardiology, 2013, 164, 255-258.	0.8	10
56	Updates in Antiplatelet Agents Used in Cardiovascular Diseases. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 514-524.	1.0	23
57	Discovery of Octahydroindenes as PAR1 Antagonists. ACS Medicinal Chemistry Letters, 2013, 4, 1054-1058.	1.3	14

#	ARTICLE	IF	CITATIONS
58	Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. <i>Nature Medicine</i> , 2013, 19, 1609-1616.	15.2	190
59	Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. <i>Journal of Molecular Medicine</i> , 2013, 91, 1257-1271.	1.7	97
60	Dual Antiplatelet Therapy Dilemmas: Duration and Choice of Antiplatelets in Acute Coronary Syndromes. <i>Current Cardiology Reports</i> , 2013, 15, 405.	1.3	5
61	Pharmacology of Antiplatelet Agents. <i>Current Atherosclerosis Reports</i> , 2013, 15, 371.	2.0	23
62	Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition. <i>Translational Research</i> , 2013, 161, 414-420.	2.2	4
63	Preserved thrombin-induced platelet activation in thienopyridine-treated patients. <i>European Journal of Clinical Investigation</i> , 2013, 43, 689-697.	1.7	15
64	Inflammation and coagulation in atherosclerosis. <i>Hamostaseologie</i> , 2013, 33, 269-282.	0.9	36
65	Prasugrel Reduces Agonists-Inducible Platelet Activation and Leukocyte-Platelet Interaction more efficiently than Clopidogrel. <i>Cardiovascular Therapeutics</i> , 2013, 31, e40-5.	1.1	27
66	Low-Dose Anticoagulation for Secondary Prevention in Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2013, 111, 618-626.	0.7	12
67	PAR-1 antagonists: current state of evidence. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 1-9.	1.0	15
68	Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 209-222.	1.0	4
69	Tratamiento mdico del angor. <i>Medicine</i> , 2013, 11, 2198-2206.	0.0	0
70	Qu ha habido de nuevo en riesgo vascular en el ao 2012?. <i>Revista Clinica Espanola</i> , 2013, 213, 442-452.	0.2	6
71	The nuances of new antiplatelet drugs in acute coronary syndrome. <i>Journal of Indian College of Cardiology</i> , 2013, 3, 16-23.	0.1	1
72	New antiplatelet agents for cardiovascular disease. <i>Cmaj</i> , 2013, 185, 1405-1411.	0.9	10
73	Residual platelet activation through protease-activated receptors (PAR)-1 and  in patients on P2Y12 inhibitors. <i>International Journal of Cardiology</i> , 2013, 168, 403-406.	0.8	28
74	Prevalence, Consequences, and Implications for Clinical Trials of Unrecognized Myocardial Infarction. <i>American Journal of Cardiology</i> , 2013, 111, 914-918.	0.7	61
75	The Year in Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1131-1143.	1.2	22

#	ARTICLE	IF	CITATIONS
77	General mechanisms of coagulation and targets of anticoagulants (Section I). <i>Thrombosis and Haemostasis</i> , 2013, 109, 569-579.	1.8	165
78	Novel Anti-platelet Agents: Focus on Thrombin Receptor Antagonists. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 415-424.	1.1	22
79	Management of Asymptomatic Carotid Artery Stenosis. Current Treatment Options in <i>Cardiovascular Medicine</i> , 2013, 15, 252-263.	0.4	1
80	Response to antiplatelet therapy is independent of endogenous thrombin generation potential. <i>Thrombosis Research</i> , 2013, 132, e24-e30.	0.8	11
81	Vorapaxar prevents progression of peripheral artery disease. <i>Nature Reviews Cardiology</i> , 2013, 10, 367-368.	6.1	1
82	Planning and evaluating clinical trials with composite time-to-first event endpoints in a competing risk framework. <i>Statistics in Medicine</i> , 2013, 32, 3595-3608.	0.8	19
83	Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 233-250.	1.0	36
84	Acute Coronary Syndromes: Advances in Antithrombotics. <i>Current Atherosclerosis Reports</i> , 2013, 15, 318.	2.0	3
85	Antiplatelet therapy: new pharmacological agents and changing paradigms. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 316-329.	1.9	61
86	Several platelet receptors and their ligands are involved in platelet-dependent thrombus formation. <i>Thrombosis Research</i> , 2013, 132, 313.	0.8	1
87	Triple versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Adding Cilostazol to Aspirin and Clopidogrel?. <i>Cardiology</i> , 2013, 126, 233-243.	0.6	11
88	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	1.0	3,915
89	Clopidogrel Added to Aspirin Adds No Benefit but Bleeding Risk in Patients With Recent Lacunar Stroke. <i>Stroke</i> , 2013, 44, 861-863.	1.0	11
90	The top 10 drug trends right now. <i>Nursing Management</i> , 2013, 44, 34-40.	0.2	0
91	Predictors for Recurrent Primary Intracerebral Hemorrhage. <i>Stroke</i> , 2013, 44, 585-590.	1.0	35
92	Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke. <i>Stroke</i> , 2013, 44, 691-698.	1.0	89
94	A History of Stroke/Transient Ischemic Attack Indicates High Risks of Cardiovascular Event and Hemorrhagic Stroke in Patients With Coronary Artery Disease. <i>Circulation</i> , 2013, 127, 730-738.	1.6	74
95	Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis. <i>Pharmaceuticals</i> , 2013, 6, 915-928.	1.7	10

#	ARTICLE	IF	CITATIONS
96	Diagnosis and Management of Ischemic Heart Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 202-213.	1.5	59
97	Protease-Activated Receptor 1 Inhibition by SCH79797 Attenuates Left Ventricular Remodeling and Profibrotic Activities of Cardiac Fibroblasts. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 460-475.	1.0	60
98	Stable Ischemic Heart Disease/Chronic Stable Angina. , 2013, , 131-152.		0
99	Vorapaxar in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2013, 127, 1522-1529.	1.6	261
100	The Influence of Multiple-Dose Vorapaxar, an Oral PAR-1 Receptor Antagonist, on the Single-Dose Pharmacokinetics and Pharmacodynamics of Digoxin. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 90-98.	0.8	4
101	Impact and Diagnosis of Antiplatelet Therapy Resistance in Patients Undergoing Cardiac Surgery. <i>Drug Development Research</i> , 2013, 74, 492-504.	1.4	1
102	Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. <i>European Heart Journal</i> , 2013, 34, 894-902.	1.0	21
103	Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA[CER]) trial. <i>European Heart Journal</i> , 2013, 34, 1723-1731.	1.0	36
104	Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: Rationale and design. <i>International Journal of Stroke</i> , 2013, 8, 479-483.	2.9	135
105	The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 540-549.	1.0	19
107	Ticagrelor for acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1473-1484.	0.6	3
108	Novel Anti-platelet Agents for the Treatment of Stable Angina Pectoris. <i>Current Pharmaceutical Design</i> , 2013, 19, 1581-1586.	0.9	1
109	High on-treatment platelet reactivity - why should we be concerned?. <i>Thrombosis and Haemostasis</i> , 2013, 109, 789-791.	1.8	7
110	Novel antiplatelet drugs in clinical development. <i>Thrombosis and Haemostasis</i> , 2013, 110, 868-875.	1.8	22
111	Modulation of Protease Activated Receptor 1 Influences Human Metapneumovirus Disease Severity in a Mouse Model. <i>PLoS ONE</i> , 2013, 8, e72529.	1.1	33
113	Vorapaxar. <i>Italian Journal of Medicine</i> , 0, , 88-95.	0.2	0
114	Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar. <i>Vascular Health and Risk Management</i> , 2014, 10, 177.	1.0	13
115	Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2014, 112, 883-891.	1.8	27

#	ARTICLE	IF	CITATIONS
116	Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 321.	0.9	5
117	Subgroup analyses with special reference to the effect of antiplatelet agents in acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2014, 112, 16-25.	1.8	3
118	Redundancy and Interaction of Thrombin- and Collagen-Mediated Platelet Activation in Tail Bleeding and Carotid Thrombosis in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2563-2569.	1.1	29
120	Pharmacology: A new bleeding issue. <i>British Dental Journal</i> , 2014, 217, 54-55.	0.3	1
121	Future prospects for contact factors as therapeutic targets. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 52-59.	0.9	19
122	Differential Signaling by Protease-Activated Receptors: Implications for Therapeutic Targeting. <i>International Journal of Molecular Sciences</i> , 2014, 15, 6169-6183.	1.8	34
123	Platelets and their chemokines in atherosclerosis—clinical applications. <i>Frontiers in Physiology</i> , 2014, 5, 294.	1.3	104
124	The global percutaneous shuttling technique tip for arthroscopic rotator cuff repair. <i>Orthopedic Reviews</i> , 2014, 6, 5279.	0.3	1
125	Inhibiting thrombosis without causing bleeding: can EP3 blockers fulfil the dream?. <i>Cardiovascular Research</i> , 2014, 101, 335-338.	1.8	4
126	Coronary Stent Thrombosis With Vorapaxar Versus Placebo. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2309-2317.	1.2	41
128	Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2014, 35, 209-215.	1.0	224
131	Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 963-976.	0.6	0
132	Proteinase-activated receptors in fibroproliferative lung disease. <i>Thorax</i> , 2014, 69, 190-192.	2.7	81
133	Patterns of Long-term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the <sc>TIMI</sc>â€“38 Coronary Stent Registry. <i>Clinical Cardiology</i> , 2014, 37, 293-299.	0.7	5
134	New Antithrombotics for Secondary Prevention of Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2014, 37, 178-187.	0.7	20
135	Vorapaxar, Combination Antiplatelet Therapy, and Stroke— <i>Journal of the American College of Cardiology</i> , 2014, 64, 2327-2329.	1.2	3
136	Vorapaxar with or without clopidogrel after nonâ€“ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial. <i>American Heart Journal</i> , 2014, 168, 869-877.e1.	1.2	21
137	Effect of the thrombin receptor antagonist (PARâ€“1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placeboâ€“and positiveâ€“controlled, parallel group trial. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 18-24.	0.8	8



#	ARTICLE	IF	CITATIONS
138	New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2318-2326.	1.2	30
139	Role of Clinical Pharmacology in the Development of Antiplatelet Drugs. <i>Clinical Therapeutics</i> , 2014, 36, 2096-2111.	1.1	8
140	Race Differences in Platelet Reactivity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2524-2526.	1.1	6
141	The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome. <i>Current Medical Research and Opinion</i> , 2014, 30, 2151-2167.	0.9	2
142	Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	9
143	Antiplatelet Treatment in the Secondary Prevention of Coronary and Cerebrovascular Disease. <i>Angiology</i> , 2014, 65, 473-490.	0.8	3
144	Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty. <i>Atherosclerosis</i> , 2014, 232, 119-124.	0.4	31
145	Evidence for compliance with long-term medication: a systematic review of randomised controlled trials. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 128-135.	1.0	4
146	Rivaroxaban: A Review of Its Use in Acute Coronary Syndromes. <i>Drugs</i> , 2014, 74, 451-464.	4.9	9
147	Lessons Learned from Negative Clinical Trials Evaluating Antithrombotic Therapy for Ischemic Heart Disease. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 112-125.	1.1	0
148	Association of Thrombin Generation Potential with Platelet PAR-1 Regulation and P-Selectin Expression in Patients on Dual Antiplatelet Therapy. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 126-132.	1.1	5
149	Joint British Societies™ consensus recommendations for the prevention of cardiovascular disease (JBS3). <i>Heart</i> , 2014, 100, ii1-ii67.	1.2	441
150	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin—Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. <i>American Heart Journal</i> , 2014, 167, 437-444.e5.	1.2	89
151	Pharmacological Treatment of Acute Coronary Syndromes. , 2014, , .		2
152	Management of antiplatelet therapy resistance in cardiac surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 147, 855-862.	0.4	10
153	Targeting platelet receptor function in thrombus formation: The risk of bleeding. <i>Blood Reviews</i> , 2014, 28, 9-21.	2.8	43
154	The platelet: life on the razor's edge between hemorrhage and thrombosis. <i>Transfusion</i> , 2014, 54, 2137-2146.	0.8	2
155	Comparison of Clinical Trial Outcome Patterns in Patients Following Acute Coronary Syndromes and in Patients With Chronic Stable Atherosclerosis. <i>Clinical Cardiology</i> , 2014, 37, 337-342.	0.7	8

#	ARTICLE	IF	CITATIONS
157	Ticagrelor for the treatment of peripheral arterial disease. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1737-1743.	1.9	0
159	Himbacine-Derived Thrombin Receptor Antagonists: C7-Aminomethyl and C9a-Hydroxy Analogues of Vorapaxar. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 183-187.	1.3	2
160	Successes and future objectives in acute coronary syndrome. <i>Nature Reviews Cardiology</i> , 2014, 11, 624-625.	6.1	5
161	Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). <i>American Heart Journal</i> , 2014, 168, 588-596.	1.2	44
162	Expression of Protease Activated Receptor-1 in Chronic Periodontitis. <i>Journal of Periodontology</i> , 2014, 85, 1763-1769.	1.7	12
163	Vorapaxar: First Global Approval. <i>Drugs</i> , 2014, 74, 1153-1163.	4.9	22
164	Usefulness and Safety of Vorapaxar in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014, 114, 665-673.	0.7	17
166	PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 423-429.	1.0	18
167	Secondary Prevention Strategies for Acute Coronary Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 844-848.	0.4	5
168	Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?. <i>American Heart Journal</i> , 2014, 168, 611-621.	1.2	34
169	Estrategias de prevención secundaria del síndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 844-848.	0.6	15
171	Vorapaxar in Patients Undergoing Coronary Artery Bypass Grafting. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1058-1060.	1.2	1
173	Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1048-1057.	1.2	40
174	Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes. <i>Circulation Research</i> , 2014, 114, 1929-1943.	2.0	79
175	Himbacine-Derived Thrombin Receptor Antagonists: C <sub>7</sub> -Spirocyclic Analogues of Vorapaxar. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 561-565.	1.3	12
176	Functional role of protease activated receptors in vascular biology. <i>Vascular Pharmacology</i> , 2014, 62, 72-81.	1.0	81
177	Potential of proteinase-activated receptors as a novel target for treatment of pulmonary hypertension. <i>Folia Pharmacologica Japonica</i> , 2014, 143, 182-186.	0.1	0
178	Clopidogrel for Smokers and Aspirin for Nonsmokers?: Not So Fast. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 585-587.	2.3	1

#	ARTICLE	IF	CITATIONS
179	Is platelet transfusion the solution to reverse platelet inhibition in patients on triple antiplatelet therapy?. <i>Thrombosis Research</i> , 2015, 136, 1057-1058.	0.8	1
180	Antiplatelet drugs: which targets for which treatments?. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, S313-S322.	1.9	47
181	Platelets: Small in Size But Essential in the Regulation of Vascular Homeostasisâ€œ Translation From Basic Science to Clinical Medicine â€œ. <i>Circulation Journal</i> , 2015, 79, 1871-1881.	0.7	26
182	Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. <i>Blood</i> , 2015, 125, 1976-1985.	0.6	71
183	The first specific antiplatelet antidote. <i>Blood</i> , 2015, 125, 3372-3374.	0.6	2
184	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2015, 68, 1125.	0.4	57
185	Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model. <i>Thrombosis Research</i> , 2015, 136, 1216-1223.	0.8	9
186	The role of antiplatelet therapy in patients with peripheral artery disease and lower extremity peripheral artery revascularization. <i>Current Opinion in Cardiology</i> , 2015, 30, 525-535.	0.8	7
187	Vorapaxar. <i>Cardiology in Review</i> , 2015, 23, 261-267.	0.6	8
188	Exploration of efficacy and bleeding with combined phosphoinositide 3â€kinase Î² inhibition and aspirin in man. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1494-1502.	1.9	39
189	Lost to Follow-up and Withdrawal of Consent in Contemporary Global Cardiovascular Randomized Clinical Trials. <i>Critical Pathways in Cardiology</i> , 2015, 14, 150-153.	0.2	1
190	Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1104-1112.	1.8	40
191	Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3801.	2.0	2
192	Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 95.	1.8	40
193	Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1133.	0.9	6
194	Breaking boundariesâ€”coagulation and fibrinolysis at the neurovascular interface. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 354.	1.8	55
195	Current Status of Antiplatelet Therapy in Acute Coronary Syndrome. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2015, 13, 40-49.	0.4	8
196	Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE). <i>PLoS ONE</i> , 2015, 10, e0121620.	1.1	36

#	ARTICLE	IF	CITATIONS
197	Cancer after intense and prolonged antiplatelet therapies – fact or fiction?. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1100-1103.	1.8	4
198	The role of national registries. <i>European Heart Journal</i> , 2015, 36, 1155-1156.	1.0	1
199	Selection of a Suitable Patient Population for New Antiplatelet Therapy From the Large Clinical Trial Database of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events – Thrombolysis in Myocardial Infarction 50 (TRA-2P – TIMI50) Trial. <i>Circulation</i> , 2015, 131, 1041-1043.	1.6	9
200	Risks and Benefits of Triple Oral Anti-Thrombotic Therapies After Acute Coronary Syndromes and Percutaneous Coronary Intervention. <i>Drug Safety</i> , 2015, 38, 481-491.	1.4	6
201	Pharmacological Treatment and Current Management of Peripheral Artery Disease. <i>Circulation Research</i> , 2015, 116, 1579-1598.	2.0	87
202	Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, S323-S331.	1.9	21
203	Pharmacological Treatment and Prevention of Cerebral Small Vessel Disease: A Review of Potential Interventions. <i>International Journal of Stroke</i> , 2015, 10, 469-478.	2.9	146
204	Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States. <i>Journal of the American Heart Association</i> , 2015, 4, e001505.	1.6	62
205	Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. <i>Future Cardiology</i> , 2015, 11, 547-564.	0.5	17
206	Platelet Reactivity: Is There a Role to Switch?. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 278-284.	1.6	4
208	Treating coronary artery disease in patients with a history of cerebrovascular disease. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 606-611.	0.7	5
209	Neuroprotective effect of ginsenoside-Rg1 on cerebral ischemia/reperfusion injury in rats by downregulating protease-activated receptor-1 expression. <i>Life Sciences</i> , 2015, 121, 145-151.	2.0	84
210	PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. <i>Platelets</i> , 2015, 26, 236-242.	1.1	21
211	Prasugrel Plus Aspirin Beyond 12 Months Is Associated With Improved Outcomes After Taxus Libert – Paclitaxel-Eluting Coronary Stent Placement. <i>Circulation</i> , 2015, 131, 62-73.	1.6	60
212	New Approaches to Inhibiting Platelets and Coagulation. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 373-397.	4.2	44
213	Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. <i>European Heart Journal</i> , 2015, 36, 1163-1170.	1.0	604
214	Vorapaxar in Atherosclerotic Disease Management. <i>Annals of Pharmacotherapy</i> , 2015, 49, 599-606.	0.9	3
215	State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 4.	0.8	16

#	ARTICLE	IF	CITATIONS
216	Current antiplatelet agents: place in therapy and role of genetic testing. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 328-336.	1.0	2
217	Oral dual antiplatelet therapy: what have we learnt from recent trials?. <i>European Heart Journal</i> , 2015, 37, ehv377.	1.0	15
218	In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist. <i>European Journal of Pharmacology</i> , 2015, 762, 221-228.	1.7	11
219	Imaging G protein-coupled receptors while quantifying their ligand-binding free-energy landscape. <i>Nature Methods</i> , 2015, 12, 845-851.	9.0	106
220	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015, 36, ehv304.	1.0	175
221	Antiplatelet Drugs in the Management of Cardiovascular Indications. , 2015, , 953-973.		0
222	Balancing the Risks and Benefits of Long-Term Antiplatelet Therapies for Cardiovascular Disease: Clinical, Research, and Regulatory Implications. <i>Journal of the American Heart Association</i> , 2015, 4, e001897.	1.6	1
223	Novel Antiplatelet Agents in Cardiovascular Medicine. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2015, 17, 383.	0.4	3
224	Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives. <i>International Journal of Cardiology</i> , 2015, 185, 9-18.	0.8	22
225	Dual Pathway Therapy for Secondary Prevention Following Acute Coronary Syndrome. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	0.8	0
226	Secondary Prevention of Heart Disease in Women: Gaps in Care/Gaps in Knowledge—Where Do We Need to Focus Our Attention. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	0.8	0
227	Vorapaxar: A Review of Its Use in the Long-Term Secondary Prevention of Atherothrombotic Events. <i>Drugs</i> , 2015, 75, 797-808.	4.9	16
228	Secondary Prevention of Cardiovascular Disease With Vorapaxar. <i>JAMA Internal Medicine</i> , 2015, 175, 9.	2.6	10
229	Diagnosis and Management of Acute Coronary Syndrome: An Evidence-Based Update. <i>Journal of the American Board of Family Medicine</i> , 2015, 28, 283-293.	0.8	98
230	Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2015, 131, 1047-1053.	1.6	73
231	Prasugrel hydrochloride for the treatment of acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 585-596.	0.9	4
232	Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. <i>Lancet, The</i> , 2015, 386, 281-291.	6.3	209
233	Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. <i>Lancet, The</i> , 2015, 386, 292-302.	6.3	59

#	ARTICLE	IF	CITATIONS
234	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. <i>European Heart Journal</i> , 2016, 37, ehv443.	1.0	293
235	Investigational new drugs for the treatment of acute coronary syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1557-1570.	1.9	3
237	Octahydrocyclopenta[c]pyridine and octahydrocyclopenta[c]pyran analogues as a protease activated receptor 1 (PAR1) antagonist. <i>Archives of Pharmacal Research</i> , 2015, 38, 2029-2041.	2.7	4
238	Platelet Inhibitors Reduce Rupture in a Mouse Model of Established Abdominal Aortic Aneurysm. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2032-2041.	1.1	61
239	Antithrombotic therapy for stable coronary artery disease: the difficult quest for the holy balance. <i>European Heart Journal</i> , 2015, 37, ehv471.	1.0	1
240	Duration of Dual Antiplatelet Therapy After Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2015, 66, 832-847.	1.2	105
241	Review of vorapaxar for the prevention of atherothrombotic events. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2509-2522.	0.9	12
242	Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 1615-1622.	0.5	9
243	Personalized Cardiovascular Medicine Today. <i>Circulation</i> , 2015, 132, 1425-1432.	1.6	33
244	Fundamentals of Clinical Trials. , 2015, , .		603
245	Antiplatelet therapy in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2133-2147.	0.9	30
246	Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 267-277.	1.6	22
247	Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis of Randomized Controlled Trials. <i>Value in Health Regional Issues</i> , 2015, 6, 22-32.	0.5	4
248	Cardiovascular Effects of Exposure to Cigarette Smoke and Electronic Cigarettes. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1378-1391.	1.2	164
249	Vorapaxar for secondary stroke prevention: perspectives and obstacles. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 1377-1382.	1.4	3
250	The FDA report on vorapaxar in the elderly: A convoluted dilemma. <i>International Journal of Cardiology</i> , 2015, 201, 601-603.	0.8	4
251	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2015, 132, 1871-1879.	1.6	39
252	Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes. <i>Journal of the American Heart Association</i> , 2015, 4, e001512.	1.6	19

#	ARTICLE	IF	CITATIONS
253	Vorapaxar in the secondary prevention of atherothrombosis. Expert Review of Cardiovascular Therapy, 2015, 13, 1293-1305.	0.6	13
254	Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?. Expert Review of Cardiovascular Therapy, 2015, 13, 1333-1344.	0.6	7
255	Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent. Blood Reviews, 2015, 29, 179-189.	2.8	43
256	Antiplatelet Therapy for Peripheral Arterial Disease and Critical Limb Ischemia. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 144-156.	1.0	17
257	Novel antiplatelet agents in acute coronary syndrome. Nature Reviews Cardiology, 2015, 12, 30-47.	6.1	299
258	Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar. Vascular Health and Risk Management, 2016, 12, 263.	1.0	8
259	Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis. Thrombosis and Haemostasis, 2016, 115, 615-621.	1.8	35
260	Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation. Thrombosis and Haemostasis, 2016, 115, 905-910.	1.8	5
261	Drug Treatment of Stable Coronary Artery Disease. , 2016, , 167-177.		1
262	Efficacy and safety of vorapaxar for the prevention of adverse cardiac events in patients with coronary artery disease: a meta-analysis. Cardiovascular Diagnosis and Therapy, 2016, 6, 101-108.	0.7	3
263	Ticagrelor and heart surgery controversy: we may have better antiplatelet options. Journal of Thoracic Disease, 2016, 8, 3016-3019.	0.6	0
264	Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis "Task Force on Anticoagulants in Heart Disease. Thrombosis and Haemostasis, 2016, 115, 685-711.	1.8	24
265	Percutaneous Coronary Intervention. , 2016, , 179-194.		7
266	Inhibition of Protease-Activated Receptor 1 Does not Affect Dendritic Homeostasis of Cultured Mouse Dentate Granule Cells. Frontiers in Neuroanatomy, 2016, 10, 64.	0.9	4
267	Association between Stable Coronary Artery Disease and In Vivo Thrombin Generation. Cardiology Research and Practice, 2016, 2016, 1-5.	0.5	11
268	Antiplatelet and Anticoagulation Treatment in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Cardiology in Review, 2016, 24, 170-176.	0.6	2
269	Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood. Journal of Thrombosis and Haemostasis, 2016, 14, 1642-1654.	1.9	42
271	Protease-activated receptor 4: from structure to function and back again. British Journal of Pharmacology, 2016, 173, 2952-2965.	2.7	42

#	ARTICLE	IF	CITATIONS
272	Vascular Complications of Diabetes. <i>Circulation Research</i> , 2016, 118, 1771-1785.	2.0	262
273	State of the art: Oral antiplatelet therapy. <i>JRSM Cardiovascular Disease</i> , 2016, 5, 204800401665251.	0.4	6
276	Management standards for stable coronary artery disease in India. <i>Indian Heart Journal</i> , 2016, 68, S31-S49.	0.2	11
277	Diagnosis and management of heart disease in the elderly. , 2016, , 157-186.		0
278	Inhibition of platelet function with clopidogrel is associated with a reduction of inflammation in patients with peripheral artery disease. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 169-175.	0.3	7
279	Management of stable angina: A commentary on the European Society of Cardiology guidelines. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1401-1412.	0.8	30
280	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2016, 37, 2315-2381.	1.0	5,370
281	Does Uncontrolled Platelet Activation Promote Coronary Artery Disease? —. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 855-857.	2.3	4
282	Vein graft failure: from pathophysiology to clinical outcomes. <i>Nature Reviews Cardiology</i> , 2016, 13, 451-470.	6.1	220
283	Antiplatelet therapy — a summary for the general physicians. <i>Clinical Medicine</i> , 2016, 16, 152-160.	0.8	36
284	Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. <i>Endoscopy</i> , 2016, 48, 385-402.	1.0	170
285	Cross Talk Pathways Between Coagulation and Inflammation. <i>Circulation Research</i> , 2016, 118, 1392-1408.	2.0	418
286	Continued vorapaxar versus withdrawn clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial. <i>International Journal of Cardiology</i> , 2016, 215, 273-276.	0.8	1
287	Antiplatelet Management for Coronary Heart Disease: Advances and Challenges. <i>Current Atherosclerosis Reports</i> , 2016, 18, 35.	2.0	12
288	Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or <sc>TIA</sc>: Insights From the <sc>REACH</sc> Registry. <i>Clinical Cardiology</i> , 2016, 39, 670-677.	0.7	45
289	Protease-activated receptors in hemostasis. <i>Blood</i> , 2016, 128, 169-177.	0.6	108
291	Do randomized clinical trial selection criteria reflect levels of risk as observed in a general population of acute myocardial infarction survivors? The PEGASUS trial in the light of the FAST-MI 2005 registry. <i>International Journal of Cardiology</i> , 2016, 223, 604-610.	0.8	12
292	Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects. <i>Clinical and Translational Science</i> , 2016, 9, 221-227.	1.5	9



#	ARTICLE	IF	CITATIONS
293	New directions for pharmacotherapy in the treatment of acute coronary syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2291-2306.	0.9	15
294	Thrombin Stimulated Platelet-Derived Exosomes Inhibit Platelet-Derived Growth Factor Receptor-Beta Expression in Vascular Smooth Muscle Cells. <i>Cellular Physiology and Biochemistry</i> , 2016, 38, 2348-2365.	1.1	86
295	SePARating thrombosis and hemostasis?. <i>Thrombosis Research</i> , 2016, 145, 140-142.	0.8	1
296	Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. <i>Nature Reviews Cardiology</i> , 2016, 13, 609-622.	6.1	24
297	Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2Â°P)â€”TIMI 50. <i>Journal of the American Heart Association</i> , 2016, 5,	1.6	13
298	Protease-activated Receptor-4 Signaling and Trafficking Is Regulated by the Clathrin Adaptor Protein Complex-2 Independent of Î²-Arrestins. <i>Journal of Biological Chemistry</i> , 2016, 291, 18453-18464.	1.6	25
299	Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease. <i>Circulation Journal</i> , 2016, 80, 791-801.	0.7	16
300	Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes. <i>Heart</i> , 2016, 102, 882-892.	1.2	3
301	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>Atherosclerosis</i> , 2016, 252, 207-274.	0.4	415
302	Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. <i>Circulation</i> , 2016, 134, 304-313.	1.6	143
303	Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries. <i>American Heart Journal</i> , 2016, 179, 10-18.	1.2	14
304	Trans-fused 5-[(tert-Butoxycarbonyl)amino]octahydroindenes as a protease activated receptor-1 (PAR1) antagonist. <i>Archives of Pharmacal Research</i> , 2016, 39, 1275-1295.	2.7	2
305	A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 285-295.	1.0	1
306	Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies. <i>Thrombosis Journal</i> , 2016, 14, 29.	0.9	141
307	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehw454.	1.0	86
308	Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2157-2164.	1.1	39
309	Appropriate Use of Vorapaxar in Patients With Peripheral Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2165-2166.	1.1	1
310	Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2016, 116, S2-S12.	1.8	7

#	ARTICLE	IF	CITATIONS
311	Using Mendelian Randomization Studies to Assess Causality and Identify New Therapeutic Targets in Cardiovascular Medicine. <i>Current Genetic Medicine Reports</i> , 2016, 4, 207-212.	1.9	4
312	Vorapaxar. <i>Coronary Artery Disease</i> , 2016, 27, 604-615.	0.3	5
313	The Development of Therapeutics for Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2729-2731.	1.2	1
314	Anticoagulation-related nephropathy. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 461-467.	1.9	80
315	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2016, 23, NP1-NP96.	0.8	683
316	Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 464-474.	1.0	18
317	Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? The Example of Vorapaxar. <i>Cardiology</i> , 2016, 133, 69-72.	0.6	1
318	Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence. <i>European Heart Journal</i> , 2016, 37, 353-364.	1.0	64
319	A Central Role for Monocyte-Platelet Interactions in Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 245-261.	1.0	22
320	Dual pathway therapy in acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 254-260.	1.0	11
321	Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges. <i>Vascular Pharmacology</i> , 2016, 81, 1-14.	1.0	8
322	Protease-Activated Receptor 4 Variant p.Tyr157Cys Reduces Platelet Functional Responses and Alters Receptor Trafficking. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 952-960.	1.1	18
323	Peripheral Artery Disease. <i>New England Journal of Medicine</i> , 2016, 374, 861-871.	13.9	214
324	Clinical Outcome of First vs Second Generation DES According to DAPT Duration: Results of ARCTIC-Generation. <i>Clinical Cardiology</i> , 2016, 39, 192-200.	0.7	7
325	Protease receptor antagonism to target blood platelet therapies. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 72-81.	2.3	10
326	Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2P-TIMI 50). <i>American Journal of Cardiology</i> , 2016, 117, 1055-1058.	0.7	5
327	Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial. <i>International Journal of Stroke</i> , 2016, 11, 614-617.	2.9	3
328	Role of Vorapaxar After Coronary Revascularization. <i>American Journal of Cardiology</i> , 2016, 117, 1059-1064.	0.7	2

#	ARTICLE	IF	CITATIONS
329	Platelet Function Testing in Patients on Antiplatelet Medications. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 306-320.	1.5	35
330	Indicaciones y duraci3n de las combinaciones de antiagregantes. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2016, 23, 29-34.	0.0	0
331	Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2016, 133, 997-1005.	1.6	163
332	In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. <i>Platelets</i> , 2016, 27, 308-316.	1.1	6
333	Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1338-1357.	1.2	144
334	Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. <i>Gut</i> , 2016, 65, 374-389.	6.1	225
335	Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary Syndromes. <i>Drugs and Aging</i> , 2016, 33, 233-248.	1.3	6
336	Platelet Physiology. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 191-204.	1.5	233
337	Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage. <i>Neurocritical Care</i> , 2016, 24, 6-46.	1.2	550
338	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e002995.	1.4	12
339	The FDA review on data quality and conduct in vorapaxar trials: Much better than in PLATO, but still not perfect. <i>International Journal of Cardiology</i> , 2016, 205, 13-16.	0.8	1
340	Vorapaxar and optimal aspirin dose: The FDA outlook. <i>International Journal of Cardiology</i> , 2016, 203, 903-905.	0.8	2
341	Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 656-662.	1.0	7
342	The management of antithrombotic agents for patients undergoing GI endoscopy. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 3-16.	0.5	538
343	Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 321-334.	2.3	3
344	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	1.0	5,890
345	Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2. <i>Oncogene</i> , 2016, 35, 1529-1540.	2.6	38
346	Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 155-163.	0.4	1

#	ARTICLE	IF	CITATIONS
347	Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2 <sup>Â</sup> P-TIMI 50 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 164-172.	0.4	8
348	Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis. <i>American Journal of Therapeutics</i> , 2017, 24, e730-e736.	0.5	4
349	Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?. <i>American Journal of Therapeutics</i> , 2017, 24, e139-e143.	0.5	5
350	The Intracranial-B&lt;sub&gt;2&lt;/sub&gt;LEED&lt;sub&gt;3&lt;/sub&gt;S Score and the Risk of Intracranial Hemorrhage in Ischemic Stroke Patients Under Antiplatelet Treatment. <i>Cerebrovascular Diseases</i> , 2017, 43, 145-151.	0.8	17
351	Predictors of long-term outcomes after bypass grafting versus drug-eluting stent implantation for left main or multivessel coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 177-185.	0.7	7
352	Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease. <i>Drugs in R and D</i> , 2017, 17, 65-72.	1.1	33
353	Execution time determines the outcome of the multicenter randomized controlled trials. <i>International Journal of Cardiology</i> , 2017, 230, 103-107.	0.8	1
354	Oral antiplatelet agents for the management of acute coronary syndromes. <i>Journal of the American Association of Nurse Practitioners</i> , 2017, 29, 104-115.	0.5	2
355	Contemporary Outcomes of Endovascular Intervention for Critical Limb Ischemia. <i>Interventional Cardiology Clinics</i> , 2017, 6, 251-259.	0.2	7
356	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-“ST-Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017, 63, 573-584.	1.5	26
357	Targeting a Proteinase-Activated Receptor 4 (PAR4) Carboxyl Terminal Motif to Regulate Platelet Function. <i>Molecular Pharmacology</i> , 2017, 91, 287-295.	1.0	23
358	Antithrombotic therapy for patients with STEMI undergoing primary PCI. <i>Nature Reviews Cardiology</i> , 2017, 14, 361-379.	6.1	76
359	Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 519-527.	1.0	10
360	Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 339-350.	1.5	2
361	Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 911-921.	1.2	157
362	Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term risk, clinical manaGement and healthcare Resource utilization of stable coronary artery dlSease (TIGRIS) observational study. <i>International Journal of Cardiology</i> , 2017, 236, 54-60.	0.8	27
363	Medical management of acute coronary syndromes. <i>Journal of the American Association of Nurse Practitioners</i> , 2017, 29, 224-235.	0.5	1
364	2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary. <i>Vascular Medicine</i> , 2017, 22, NP1-NP43.	0.8	162

#	ARTICLE	IF	CITATIONS
365	First, do no (irreparable) harm: infarction, bleeding, and subsequent risk of death. The dangers of false equivalency. <i>European Heart Journal</i> , 2017, 38, ehw639.	1.0	0
366	Vorapaxar in secondary prevention: where we stand. <i>Current Medical Research and Opinion</i> , 2017, 33, 2077-2079.	0.9	1
367	Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 88-100.	0.8	45
368	Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 61-70.	0.8	20
369	Medical Therapy and Recurrent Ischemic Events in High Risk Patients Surviving their Myocardial Infarction for at Least 12 Months: Comparison of Patients with ST Elevation Versus Non-ST Elevation Myocardial Infarction. <i>Cardiology and Therapy</i> , 2017, 6, 273-280.	1.1	9
370	Medical management of claudication. <i>Journal of Vascular Surgery</i> , 2017, 66, 275-280.	0.6	22
371	Vorapaxar in the long-term secondary prevention of atherothrombotic events: a profile of its use in the USA. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 254-259.	0.3	0
372	A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization. <i>Circulation</i> , 2017, 135, 2534-2555.	1.6	136
373	Oral antiplatelet therapy: impact for transfusion medicine. <i>Vox Sanguinis</i> , 2017, 112, 511-517.	0.7	11
375	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	0.8	133
376	2016 American College of Cardiology/American Heart Association Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Perioperative Implications. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, 1543-1553.	0.6	3
377	Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry. <i>Clinical Cardiology</i> , 2017, 40, 710-718.	0.7	33
378	Targeting PAR1: Now What?. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 701-716.	4.0	70
379	How I use laboratory monitoring of antiplatelet therapy. <i>Blood</i> , 2017, 130, 713-721.	0.6	42
380	State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. <i>Current Medical Research and Opinion</i> , 2017, 33, 1535-1543.	0.9	2
381	Antiplatelet therapy in acute coronary syndrome. <i>Continuing Cardiology Education</i> , 2017, 3, 11-21.	0.4	1
382	2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, e71-e126.	1.2	972
383	Statistical planning to address strongly correlated endpoints for inferential subgroups: An innovative approach for an illustrative clinical trial with complex multiplicity issues. <i>Journal of Biopharmaceutical Statistics</i> , 2017, 27, 399-415.	0.4	2

#	ARTICLE	IF	CITATIONS
384	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>International Journal of Behavioral Medicine</i> , 2017, 24, 321-419.	0.8	84
385	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2 <sup>Â</sup> P - TIMI 50 Trial. <i>Clinical Chemistry</i> , 2017, 63, 307-315.	1.5	19
386	Antiplatelet Therapy for Secondary Prevention After Acute Myocardial Infarction. <i>Interventional Cardiology Clinics</i> , 2017, 6, 119-129.	0.2	2
387	2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2017, 135, e686-e725.	1.6	529
388	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	6
389	Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	124
390	Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIb/IIIa Activation in Human Platelets. <i>Molecular Pharmacology</i> , 2017, 91, 39-47.	1.0	29
391	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1760-1776.	1.2	140
392	Contemporary Use of Oral Antithrombotic Agents: Focus on Dual and Triple Therapeutic Approaches. <i>Pharmacotherapy</i> , 2017, 37, 1545-1564.	1.2	0
393	Tailoring naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and in vitro evaluation. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 2609-2618.	1.1	13
394	An Important Step for Thrombocardiology. <i>New England Journal of Medicine</i> , 2017, 377, 1387-1388.	13.9	18
395	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	13.9	1,745
396	Paradigm of Biased PAR1 (Protease-Activated Receptor-1) Activation and Inhibition in Endothelial Cells Dissected by Phosphoproteomics. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1891-1902.	1.1	18
397	Management of antithrombotic agents in patients undergoing flexible bronchoscopy. <i>European Respiratory Review</i> , 2017, 26, 170001.	3.0	22
398	Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 527-538.	1.2	23
399	Discovery of Potent Orally Active Protease-Activated Receptor 1 (PAR1) Antagonists Based on Andrographolide. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7166-7185.	2.9	16
400	Antiplatelet Therapy in Noncardioembolic Stroke: A Review of Current Evidence. <i>Seminars in Neurology</i> , 2017, 37, 366-375.	0.5	0
401	Update on antithrombotic therapy after percutaneous coronary revascularisation. <i>Lancet, The</i> , 2017, 390, 810-820.	6.3	25

#	ARTICLE	IF	CITATIONS
402	Anticoagulation-Related Nephropathy: Tip of the Iceberg. , 2017, , 295-299.		0
404	Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications. Current Atherosclerosis Reports, 2017, 19, 56.	2.0	16
405	Platelet pathophysiology, pharmacology, and function in coronary artery disease. Coronary Artery Disease, 2017, 28, 614-623.	0.3	22
406	Protease-activated receptor-4 and purinergic receptor P2Y12 dimerize, co-internalize, and activate Akt signaling via endosomal recruitment of $\beta$ -arrestin. Journal of Biological Chemistry, 2017, 292, 13867-13878.	1.6	36
407	Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic) Tj ETQq0 0.6gBT /Ovz8 Block 10 T	0.6	28
408	2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary. Journal of the American College of Cardiology, 2017, 69, 1465-1508.	1.2	462
409	Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. New England Journal of Medicine, 2017, 376, 32-40.	13.9	494
410	2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2017, 135, e726-e779.	1.6	571
411	Safety and efficacy of vorapaxar in secondary prevention of atherosclerotic disease: A meta-analysis of randomized control trials. International Journal of Cardiology, 2017, 227, 617-624.	0.8	16
412	Acute myocardial infarction. Lancet, The, 2017, 389, 197-210.	6.3	869
413	Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 133-141.	1.0	2
414	Challenges and Opportunities in Protease-Activated Receptor Drug Development. Annual Review of Pharmacology and Toxicology, 2017, 57, 349-373.	4.2	50
415	Pharmacological secondary prevention in patients with mesenteric artery atherosclerosis and arterial embolism. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 105-109.	1.0	4
416	Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1258-1264.	1.8	40
418	Atherosclerosis to predict cardiac events. Journal of Cardiovascular Medicine, 2017, 18, e154-e156.	0.6	3
419	Antithrombotic therapy for acute coronary syndrome: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1240-1248.	1.8	41
420	Platelets, Haemostasis and Inflammation. Cardiac and Vascular Biology, 2017, , .	0.2	5
421	Platelets and Stroke. Cardiac and Vascular Biology, 2017, , 253-274.	0.2	1

#	ARTICLE	IF	CITATIONS
422	Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context. <i>Cardiovascular Research</i> , 2017, 113, e61-e63.	1.8	6
423	Platelet receptors as therapeutic targets: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1249-1257.	1.8	57
424	Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of Emergency Medicine (SIMELU) and Italian Society of Interventional Cardiology (SICI-GISE). <i>European Heart Journal Supplements</i> , 2017, 19, D130-D150.	0.0	4
425	Thrombin is a selective inducer of heparanase release from platelets and granulocytes via protease-activated receptor-1. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1391-1401.	1.8	18
426	Pharmacological update: New drugs in cardiac practice: A critical appraisal. <i>Annals of Cardiac Anaesthesia</i> , 2017, 20, 49.	0.3	4
427	Peripheral interventions and antiplatelet therapy: Role in current practice. <i>World Journal of Cardiology</i> , 2017, 9, 583.	0.5	22
428	Antiplatelet therapy for prevention of ischemic stroke. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2017, 28, 326-334.	0.1	0
429	Medical Treatment of Intracranial Atherosclerosis: An Update. <i>Journal of Stroke</i> , 2017, 19, 261-270.	1.4	30
430	Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications. <i>Korean Journal of Anesthesiology</i> , 2017, 70, 13.	0.9	17
431	Changes in Treatment Patterns and Incremental Health Care Utilization Due to P2Y12-Associated Complications in Patients with Acute Coronary Syndrome. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, 947-956.	0.5	1
432	Antiplatelet Agents. , 2017, , 874-881.		1
433	Primary and secondary prevention in diabetic patients. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, e83-e90.	0.6	0
434	Peripheral artery disease and antiplatelet treatment. <i>Current Opinion in Pharmacology</i> , 2018, 39, 43-52.	1.7	16
435	General Considerations for Neurointerventional Procedures. , 2018, , 167-246.		1
436	Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 653-665.	0.9	15
437	Noncanonical Matrix Metalloprotease 1â€“Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1368-1380.	1.1	38
438	PAR4 (Protease-Activated Receptor 4). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 287-289.	1.1	23
439	Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2018, 3, 234.	3.0	46



#	ARTICLE	IF	CITATIONS
440	Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 726-732.	1.1	20
441	More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy—Current Data and Future Directions. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	11
443	Preoperative platelet transfusions to reverse antiplatelet therapy for urgent non-cardiac surgery: an observational cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 709-717.	1.9	18
444	PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E982-E991.	3.3	55
446	The Evolving Face of Myocardial Reperfusion in Acute Coronary Syndromes: A Primer for the Internist. <i>Mayo Clinic Proceedings</i> , 2018, 93, 199-216.	1.4	1
447	Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca <sup>2+</sup> mobilization and ERK phosphorylation in healthy Japanese subjects. <i>Thrombosis Research</i> , 2018, 162, 44-52.	0.8	17
448	PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 448-456.	1.1	79
450	Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines. <i>Gut</i> , 2018, 67, 405-417.	6.1	132
451	Current and future antiplatelet therapies: emphasis on preserving haemostasis. <i>Nature Reviews Cardiology</i> , 2018, 15, 181-191.	6.1	207
452	The coagulation system in atherothrombosis: Implications for new therapeutic strategies. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 188-198.	1.0	43
453	New and upcoming treatments in antiphospholipid syndrome: A comprehensive review. <i>Pharmacological Research</i> , 2018, 133, 108-120.	3.1	7
454	External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. <i>Atherosclerosis</i> , 2018, 272, 80-86.	0.4	24
455	Platelet Signaling Pathways and New Inhibitors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, e28-e35.	1.1	41
456	Clinical effects with inhibition of multiple coagulative pathways in patients admitted for acute coronary syndrome. <i>Internal and Emergency Medicine</i> , 2018, 13, 1019-1028.	1.0	2
457	Coronary and peripheral artery atherosclerosis. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, e72-e74.	0.6	2
458	No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 143-150.	0.8	2
459	Antiplatelet and Anticoagulant Drugs. , 2018, , 303-320.		1
460	Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 23-37.	1.0	17

#	ARTICLE	IF	CITATIONS
461	Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert Review of Clinical Pharmacology, 2018, 11, 151-164.	1.3	57
462	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	1.0	2,246
463	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2018, 53, 34-78.	0.6	261
464	The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. Expert Review of Hematology, 2018, 11, 5-12.	1.0	17
465	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation, 2018, 137, 684-692.	1.6	22
466	Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?. Platelets, 2018, 29, 228-237.	1.1	3
467	The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. Journal of Thrombosis and Haemostasis, 2018, 16, 352-363.	1.9	21
468	Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia. Cardiovascular Revascularization Medicine, 2018, 19, 516-520.	0.3	20
470	Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. Diabetes Care, 2018, 41, 577-585.	4.3	25
471	Antiplatelet Therapy in Diabetes. Endocrinology and Metabolism Clinics of North America, 2018, 47, 223-235.	1.2	3
472	Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice. Oncotarget, 2018, 9, 21655-21662.	0.8	10
473	Antiplatelet therapy for peripheral artery disease. Cardiovascular Diagnosis and Therapy, 2018, 8, 663-677.	0.7	9
474	Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. Journal of the American Heart Association, 2018, 7, e009609.	1.6	9
475	Diabetes and antiplatelet therapy: from bench to bedside. Cardiovascular Diagnosis and Therapy, 2018, 8, 594-609.	0.7	45
476	OBSOLETE: Vascular Repair at the Interface of the Endothelium: The Roles of Protease-Activated Receptors and Neuregulin-1. , 2018, , .		0
477	Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. Future Cardiology, 2018, 14, 443-453.	0.5	6
478	A Novel Compound Targeting Protease Receptor 1 Activators for the Treatment of Glioblastoma. Frontiers in Neurology, 2018, 9, 1087.	1.1	9
479	Atherothrombotic risk stratification after acute myocardial infarction: the TIMI Risk Score for Secondary Prevention (TRS-2P) in the light of the FAST-MI registries. Clinical Cardiology, 2018, 42, 227-234.	0.7	11

#	ARTICLE	IF	CITATIONS
480	GPCR Modulation in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3840.	1.8	35
481	Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1041-1052.	1.0	20
482	Recent progress and market analysis of anticoagulant drugs. <i>Journal of Thoracic Disease</i> , 2018, 10, 2011-2025.	0.6	29
483	Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2018, 5, e553-e559.	2.1	19
484	Reversal of Systemic Anticoagulants and Antiplatelet Therapeutics. <i>Neurosurgery Clinics of North America</i> , 2018, 29, 537-545.	0.8	11
486	Abdominal aortic aneurysm: screening and management. <i>Continuing Cardiology Education</i> , 2018, 4, 34-39.	0.4	0
487	Antiplatelet Treatment for Catheter-Based Interventions in High-Risk Patients: Current Guidelines and Expert Opinion. <i>Hamostaseologie</i> , 2018, 38, 229-235.	0.9	2
488	Vascular Repair at the Interface of the Endothelium: The Roles of Protease-Activated Receptors and Neuregulin-1. , 2018, , 627-639.		0
489	A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant. <i>Blood Advances</i> , 2018, 2, 1283-1293.	2.5	24
490	Novel aspects of antiplatelet therapy in cardiovascular disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 439-449.	1.0	41
491	Antithrombotic Therapy for Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2450-2467.	1.2	43
492	Integrating platelet and coagulation activation in fibrin clot formation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 450-460.	1.0	122
493	Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease. <i>Critical Pathways in Cardiology</i> , 2018, 17, 53-68.	0.2	2
494	Diabetes and Cardiovascular Disease. , 2018, , 823-838.		0
495	Astrocytes and the Warning Signs of Intracerebral Hemorrhagic Stroke. <i>Neural Plasticity</i> , 2018, 2018, 1-11.	1.0	25
496	Managing Antithrombotic Agents in the Setting of Acute Gastrointestinal Bleeding. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2018, 28, 351-361.	0.6	6
497	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	6.1	180
498	Antithrombotic Drugs. , 2018, , 2168-2188.		5

#	ARTICLE	IF	CITATIONS
500	Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2237.	1.8	41
501	Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 72, 37-43.	0.6	10
502	Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint. <i>International Angiology</i> , 2018, 37, 255-260.	0.4	2
503	In vivo vulnerability grading system of plaques causing acute coronary syndromes: An intravascular imaging study. <i>International Journal of Cardiology</i> , 2018, 269, 350-355.	0.8	16
504	PrÄ, peri- und postinterventionelle Antikoagulation. , 2018, , 155-159.		0
505	Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 457-472.	1.0	13
506	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. <i>European Heart Journal Supplements</i> , 2018, 20, F1-F74.	0.0	25
507	Inhibition of Protease-Activated Receptor (PAR1) Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Human Endotoxemia. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1176-1184.	1.8	33
508	Outcomes After Percutaneous Coronary Intervention in Patients With a History of Cerebrovascular Disease. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006400.	1.4	12
509	Antiplatelet and anticoagulation therapy during percutaneous coronary interventions: A review for the interventionalist. <i>Journal of Interventional Cardiology</i> , 2018, 31, 693-704.	0.5	2
510	Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy. , 2019, 193, 83-90.		16
511	Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?. <i>European Heart Journal</i> , 2019, 40, 1466-1471.	1.0	22
512	Platelets, Thrombo-Inflammation, and Cancer: Collaborating With the Enemy. <i>Frontiers in Immunology</i> , 2019, 10, 1805.	2.2	155
513	The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era. <i>Cardiovascular Research</i> , 2019, 115, e121-e124.	1.8	3
514	Targeting coagulation in heart failure with preserved ejection fraction and cardiac fibrosis. <i>European Heart Journal</i> , 2019, 40, 3333-3335.	1.0	3
515	Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071986147.	1.1	3
516	Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 383-390.	1.0	18
517	Atherosclerosis Pathogenesis and Microvascular Dysfunction. , 2019, , .		8

#	ARTICLE	IF	CITATIONS
518	Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7400-7416.	2.9	12
519	Heterogeneity of Risk and Benefit in Subgroups of COMPASS. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3292-3294.	1.2	1
520	Long-Term Risk Stratification of Patients Undergoing Coronary Angiography According to the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention. <i>Journal of the American Heart Association</i> , 2019, 8, e012433.	1.6	4
521	Role of rivaroxaban in the prevention of atherosclerotic events. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 771-780.	1.3	12
522	Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1171-1189.	1.0	23
523	Therapeutic Vaccines as Novel Immunotherapy. , 2019, , .		1
524	Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies. <i>Cancers</i> , 2019, 11, 1639.	1.7	9
525	Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease. <i>TH Open</i> , 2019, 03, e259-e262.	0.7	3
526	Cardiovascular Risk Factors and Secondary Events Among Acute and Chronic Stable Myocardial Infarction Patients: Findings from a Managed Care Database. <i>Cardiology and Therapy</i> , 2019, 8, 329-343.	1.1	3
527	Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios. <i>Current Cardiology Reports</i> , 2019, 21, 115.	1.3	17
528	Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus. <i>JACC Basic To Translational Science</i> , 2019, 4, 763-775.	1.9	12
529	Platelets Are at the Nexus of Vascular Diseases. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 132.	1.1	48
530	Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: a Review. <i>Current Cardiology Reports</i> , 2019, 21, 5.	1.3	2
531	Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. <i>Circulation Research</i> , 2019, 124, 416-425.	2.0	29
532	Outcome associated with prescription of cardiac rehabilitation according to predicted risk after acute myocardial infarction: Insights from the FAST-MI registries. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 459-468.	0.7	11
533	Global vascular guidelines on the management of chronic limb-threatening ischemia. <i>Journal of Vascular Surgery</i> , 2019, 69, 3S-125S.e40.	0.6	841
534	TIMI risk score for secondary prevention of recurrent cardiovascular events in a real-world cohort of post-non-ST-elevation myocardial infarction patients. <i>Postgraduate Medical Journal</i> , 2019, 95, 372-377.	0.9	2
535	Acute Limb Ischemia in Peripheral Artery Disease. <i>Circulation</i> , 2019, 140, 556-565.	1.6	80

#	ARTICLE	IF	CITATIONS
536	Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 58, S1-S109.e33.	0.8	741
537	Prise en charge de la maladie coronaire chronique : vers de nouvelles recommandations ?. <i>Archives of Cardiovascular Diseases Supplements</i> , 2019, 11, S28-S39.	0.0	0
540	Potential different impact of inhibition of thrombin function and thrombin generation rate for the growth of thrombi formed at site of endothelial injury under blood flow condition. <i>Thrombosis Research</i> , 2019, 179, 121-127.	0.8	8
541	The Two-way Relationship Between Cancer and Atherosclerosis. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2019, 72, 487-494.	0.4	14
542	Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke. <i>JAMA Neurology</i> , 2019, 76, 774.	4.5	38
543	Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. <i>Circulation</i> , 2019, 139, 2170-2185.	1.6	66
544	Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2Â°P-TIMI 50 trial. <i>Vascular Medicine</i> , 2019, 24, 159-161.	0.8	3
546	Acute Coronary Syndrome, Thrombocytopenia, and Antiplatelet Therapy in Critically Ill Cancer Patients. , 2019, , 1-23.		0
547	Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention of Recurrent Cardiovascular Events in a Real-World Cohort of Post-Acute Myocardial Infarction Patients. <i>Circulation Journal</i> , 2019, 83, 809-817.	0.7	7
548	Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post-acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACSâ€TIMI 46 and ATLAS ACS 2â€TIMI 51. <i>Journal of the American Heart Association</i> , 2019, 8, .	1.6	10
549	Protease-Activated Receptors. , 2019, , 243-257.		8
550	Laboratory Monitoring of Antiplatelet Therapy. , 2019, , 653-682.		0
551	Personalized benefitâ€risk assessments combining clinical trial and realâ€world data provide further insights into which patients may benefit most from therapy: Demonstration for a new oral antiplatelet therapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 443-451.	0.9	6
552	Novel Antiplatelet Therapies. , 2019, , 991-1015.		1
553	Antiplatelet Drugs in the Management of Coronary Artery Disease. , 2019, , 1017-1029.		0
554	A vaccine targeting blood clot formation: what is the potential?. <i>Expert Review of Vaccines</i> , 2019, 18, 419-421.	2.0	0
555	Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. <i>Thrombosis Journal</i> , 2019, 17, 4.	0.9	200
556	La relaciÃ³n bidireccional entre el cÃ¡ncer y la aterosclerosis. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 487-494.	0.6	15

#	ARTICLE	IF	CITATIONS
557	Novel Antiplatelet Therapies for Atherothrombotic Diseases. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 546-557.	1.1	47
558	Antithrombotics in stable peripheral artery disease. <i>Vascular Medicine</i> , 2019, 24, 132-140.	0.8	11
559	Newest Antithrombotic Agents: Uses, Challenges, and Reversal Strategies for Surgical Procedures. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , 2019, , 481-497.	0.0	0
560	Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5629.	1.8	20
561	Platelets as Modulators of Cerebral Ischemia/Reperfusion Injury. <i>Frontiers in Immunology</i> , 2019, 10, 2505.	2.2	69
562	How To Assess a Claudication and When To Intervene. <i>Current Cardiology Reports</i> , 2019, 21, 138.	1.3	12
564	Oral antiplatelets in primary and secondary prevention of myocardial infarction: a review. <i>Irish Journal of Medical Science</i> , 2019, 188, 453-467.	0.8	4
565	Investigational drugs for the treatment of acute myocardial infarction: focus on antiplatelet and anticoagulant agents. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 223-234.	1.9	7
566	The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. <i>International Journal of Cardiology</i> , 2019, 278, 7-13.	0.8	19
567	Anti-platelet and anti-coagulant therapy in peripheral arterial disease prior to surgical intervention. <i>Vascular</i> , 2019, 27, 299-311.	0.4	9
568	Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 411-419.	0.8	13
569	Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 353-360.	1.0	7
570	Unstable Angina and Non-ST Elevation Myocardial Infarction. <i>Contemporary Cardiology</i> , 2019, , 233-259.	0.0	0
571	Role of thrombin in the pathogenesis of atherosclerosis. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 4757-4765.	1.2	35
572	Antiplatelet Therapy in Cardiovascular Medicine. , 2019, , 396-414.		0
573	Anticoagulation in the Perioperative Period. , 2019, , 721-733.		0
574	Acquired platelet function disorders. <i>Thrombosis Research</i> , 2020, 196, 561-568.	0.8	8
575	Proposal for a standardized discharge letter after hospital stay for acute myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 788-801.	0.4	7

#	ARTICLE	IF	CITATIONS
576	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 296-307.	0.8	28
577	Anti-thrombotic strategies in elderly patients receiving platelet inhibitors. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 57-68.	1.4	13
578	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 86-93.	1.4	27
579	The myth of "stable" coronary artery disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 9-21.	6.1	89
580	Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 23-35.	1.9	13
581	Antiapoptotic Effect by PAR-1 Antagonist Protects Mouse Liver Against Ischemia-Reperfusion Injury. <i>Journal of Surgical Research</i> , 2020, 246, 568-583.	0.8	4
582	Molecular basis of protease-activated receptor 1 signaling diversity. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 6-16.	1.9	44
583	Molecular basis for activation and biased signaling at the thrombin-activated GPCR proteinase activated receptor-4 (PAR4). <i>Journal of Biological Chemistry</i> , 2020, 295, 2520-2540.	1.6	24
584	Platelet Transfusion in Perioperative Medicine. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 050-061.	1.5	15
585	A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation. <i>Journal of Vascular Access</i> , 2020, 21, 467-474.	0.5	1
586	Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1. <i>Circulation Research</i> , 2020, 126, 486-500.	2.0	87
587	Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications. <i>Current Atherosclerosis Reports</i> , 2020, 22, 75.	2.0	27
588	Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 881-889.	0.6	3
589	Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009584.	1.4	13
590	Research and the Future of Telematics. <i>Communications in Computer and Information Science</i> , 2020, , .	0.4	2
591	PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2990-3003.	1.1	18
592	Chronic ischaemic heart disease and rivaroxaban: which patients derive the greatest benefit?. <i>European Heart Journal Supplements</i> , 2020, 22, L24-L27.	0.0	3
593	Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus. <i>Circulation</i> , 2020, 142, 2172-2188.	1.6	26



#	ARTICLE	IF	CITATIONS
594	Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. <i>Atherosclerosis</i> , 2020, 315, 10-17.	0.4	17
595	Lipid Receptor GPR31 (G-Protein-Coupled Receptor 31) Regulates Platelet Reactivity and Thrombosis Without Affecting Hemostasis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, e33-e45.	1.1	15
596	Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices. <i>Circulation</i> , 2020, 142, 1974-1988.	1.6	7
597	Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	0.9	10
598	Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-11.	1.1	9
599	Pathogenesis and management of heparin-induced thrombocytopenia and thrombosis. <i>Clinica Chimica Acta</i> , 2020, 504, 73-80.	0.5	8
600	Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATO): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both. <i>American Heart Journal</i> , 2020, 222, 166-173.	1.2	13
601	Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry. <i>Annales De Cardiologie Et D'Angiologie</i> , 2020, 69, 158-166.	0.3	3
602	Platelets as Mediators of Neuroinflammation and Thrombosis. <i>Frontiers in Immunology</i> , 2020, 11, 548631.	2.2	72
603	New and emerging cardiovascular and antihypertensive drugs. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1315-1327.	1.0	5
604	Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events?. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 16, 607-613.	0.3	3
605	Role of the Platelets and Nitric Oxide Biotransformation in Ischemic Stroke: A Translative Review from Bench to Bedside. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-18.	1.9	32
606	Eligibility for extended antithrombotic therapy for secondary prevention of acute coronary syndrome. <i>Revista Portuguesa De Cardiologia</i> , 2020, 39, 493-501.	0.2	3
607	Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 16, 99-107.	0.3	0
608	Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. <i>Lancet, The</i> , 2020, 395, 1487-1495.	6.3	104
609	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
610	Vorapaxar in the treatment of cardiovascular diseases. <i>Future Cardiology</i> , 2020, 16, 373-384.	0.5	10
611	Novel Mouse Model for Studying Hemostatic Function of Human Platelets. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1891-1904.	1.1	7

#	ARTICLE	IF	CITATIONS
612	Blockade of PAR $\alpha$ 1 Signaling Attenuates Cardiac Hypertrophy and Fibrosis in Renin $\alpha$ Overexpressing Hypertensive Mice. <i>Journal of the American Heart Association</i> , 2020, 9, e015616.	1.6	13
613	Current and emerging drug treatment strategies for peripheral arterial disease. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1603-1616.	0.9	9
615	Therapeutic strategies for thrombosis: new targets and approaches. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 333-352.	21.5	188
616	New Antithrombotic Drugs in Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 2059.	1.0	10
617	Proteinase $\alpha$ activated receptor 1: A target for repurposing in the treatment of COVID $\alpha$ 19?. <i>British Journal of Pharmacology</i> , 2020, 177, 4971-4974.	2.7	20
619	Late intensive antithrombotic secondary prevention after myocardial infarction. When, in whom and how?. <i>Revista Colombiana De Cardiologia</i> , 2020, 27, 4-6.	0.1	0
620	Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1147-1158.	1.8	23
621	New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 15, 873-880.	0.3	0
622	Platelet Inhibition in Acute Coronary Syndrome and Percutaneous Coronary Intervention: Insights from the Past and Present. <i>Thrombosis and Haemostasis</i> , 2020, 120, 565-578.	1.8	20
623	Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. <i>International Journal of Cardiology</i> , 2020, 311, 7-14.	0.8	9
624	Novel Antiplatelet Agents in Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 191-200.	1.0	28
625	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	6.1	87
626	Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. <i>Current Cardiology Reports</i> , 2020, 22, 13.	1.3	1
629	Novel antithrombotic regimen in patients with ischemic heart disease and peripheral arterial disease: can we identify those who derive the highest benefit?. <i>Journal of Medical Economics</i> , 2020, 23, 670-672.	1.0	0
630	Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y <sub>12</sub> Receptor Inhibitors With and Without Aspirin: Results of the VORA $\alpha$ PRATIC Study. <i>Journal of the American Heart Association</i> , 2020, 9, e015865.	1.6	18
631	COVID-19 cytokine storm: the interplay between inflammation and coagulation. <i>Lancet Respiratory Medicine</i> , 2020, 8, e46-e47.	5.2	1,011
632	Proteinase-Activated Receptor 4 Activation Triggers Cell Membrane Blebbing through RhoA and $\beta$ 2-Arrestin. <i>Molecular Pharmacology</i> , 2020, 97, 365-376.	1.0	7
633	Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1351-1353.	0.8	4

#	ARTICLE	IF	CITATIONS
634	Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 21-34.	1.0	4
635	Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI. <i>Clinical Research in Cardiology</i> , 2021, 110, 759-774.	1.5	6
636	Protease-activated receptor 1 as a potential therapeutic target for COVID-19. <i>Experimental Biology and Medicine</i> , 2021, 246, 688-694.	1.1	19
637	F2R Polymorphisms and Clopidogrel Efficacy and Safety in Patients With Minor Stroke or TIA. <i>Neurology</i> , 2021, 96, e1-e9.	1.5	3
638	Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets. <i>Physiological Reviews</i> , 2021, 101, 545-567.	13.1	78
639	Clinical outcomes with high-intensity statins according to atherothrombotic risk stratification after acute myocardial infarction: The FAST-MI registries. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 88-95.	0.7	5
640	Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2 <sup>Â</sup> P-TIMI 50 Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 190-199.	0.4	5
641	Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease. <i>Heart International</i> , 2021, 15, 14.	0.4	1
642	Protease-Activated Receptors (PARs)., 2021, , 1-13.		0
644	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. <i>Circulation</i> , 2021, 143, 685-695.	1.6	22
645	Antithrombotic therapy in diabetes: which, when, and for how long?. <i>European Heart Journal</i> , 2021, 42, 2235-2259.	1.0	29
646	Modulation of Hemostasis in COVID-19; Blood Platelets May Be Important Pieces in the COVID-19 Puzzle. <i>Pathogens</i> , 2021, 10, 370.	1.2	20
647	Safety of antithrombotic therapy in East Asian patients. <i>Internal and Emergency Medicine</i> , 2021, 16, 1443-1450.	1.0	7
648	Ischemic stroke in PAR1 KO mice: Decreased brain plasmin and thrombin activity along with decreased infarct volume. <i>PLoS ONE</i> , 2021, 16, e0248431.	1.1	8
649	Improving Outcomes in Cardiovascular Diseases. <i>Cardiology in Review</i> , 2021, Publish Ahead of Print, .	0.6	4
651	Asymptomatic peripheral artery disease: Silent but deadly. <i>Progress in Cardiovascular Diseases</i> , 2021, 65, 2-8.	1.6	4
652	Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke. <i>Journal of Clinical Medicine</i> , 2021, 10, 1923.	1.0	3
653	Oral Antiplatelet Therapy After Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1545.	3.8	62

#	ARTICLE	IF	CITATIONS
654	Reducing Nontraumatic Lower-Extremity Amputations by 20% by 2030: Time to Get to Our Feet: A Policy Statement From the American Heart Association. <i>Circulation</i> , 2021, 143, e875-e891.	1.6	51
655	The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 796-802.	1.1	7
656	Validation of the atherothrombotic risk score for secondary prevention in patients with acute myocardial infarction: the J-MINUET study. <i>Heart and Vessels</i> , 2021, 36, 1506-1513.	0.5	2
657	Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1397-1413.	2.0	39
658	Considerations for use of direct oral anticoagulants in arterial disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12502.	1.0	1
659	Current state-of-the-art antiplatelet and anticoagulation therapy in diabetic patients with coronary artery disease. <i>Future Cardiology</i> , 2021, 17, 521-534.	0.5	3
660	Do we have a unified consensus on antithrombotic management of PAD?. <i>International Angiology</i> , 2021, 40, 229-239.	0.4	1
662	Potential Relation between Plasma BDNF Levels and Human Coronary Plaque Morphology. <i>Diagnostics</i> , 2021, 11, 1010.	1.3	6
663	Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. <i>Journal of the American Heart Association</i> , 2021, 10, e018684.	1.6	13
664	Contemporary Medical Management of Peripheral Artery Disease. <i>Circulation Research</i> , 2021, 128, 1868-1884.	2.0	53
665	The TIMI Study Group's Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease-. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 563-572.	0.9	1
667	Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7113.	1.8	7
668	Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. <i>European Heart Journal</i> , 2021, 42, 4013-4024.	1.0	76
669	Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. <i>European Heart Journal</i> , 2021, 42, 4040-4048.	1.0	13
670	Effects of Heparin and Bivalirudin on Thrombin-Induced Platelet Activation: Differential Modulation of PAR Signaling Drives Divergent Prothrombotic Responses. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 717835.	1.1	4
671	Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020446.	1.6	7
672	Ankle-Brachial Index Test. , 2022, , 40-43.		0
673	Peripheral arterial disease—a different kind of arterial disease? The role of antiplatelet therapy in the prevention and treatment of limb ischemia. , 2021, , 79-89.		0

#	ARTICLE	IF	CITATIONS
674	Platelet physiology and pharmacology—relevant considerations for patient care. , 2021, , 15-45.		0
675	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. , 2017, , 317-338.		19
676	Acute Coronary Syndrome, Thrombocytopenia, and Antiplatelet Therapy in Critically Ill Cancer Patients. , 2020, , 711-732.		3
677	Antithrombotic treatment in peripheral artery disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2018, 47, 99-108.	0.6	25
678	Oral antiplatelet agents in cardiovascular disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2019, 48, 291-302.	0.6	14
679	ESVM Guideline on peripheral arterial disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2019, 48, 1-79.	0.6	110
680	5 Conservative treatment for PAD — Risk factor management. <i>Vasa - European Journal of Vascular Medicine</i> , 2019, 48, 1-12.	0.6	15
681	Structure-guided design of pure orthosteric inhibitors of $\text{Î±IIbÎ²3}$ that prevent thrombosis but preserve hemostasis. <i>Nature Communications</i> , 2020, 11, 398.	5.8	27
683	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 908-918.	1.5	13
684	Proteinase-activated Receptor 1 Contributed to Up-regulation of Enkephalin in Keratinocytes of Patients with Obstructive Jaundice. <i>Anesthesiology</i> , 2014, 121, 127-139.	1.3	16
685	Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation?. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2013-2025.	1.8	31
686	PAR1 contributes to influenza A virus pathogenicity in mice. <i>Journal of Clinical Investigation</i> , 2013, 123, 206-214.	3.9	73
687	PAR-1 contributes to the innate immune response during viral infection. <i>Journal of Clinical Investigation</i> , 2013, 123, 1310-1322.	3.9	128
688	Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2Å°P-TIMI 50 trial. <i>Vascular Medicine</i> , 2020, 25, 124-132.	0.8	24
689	Targeting coagulation activation in severe COVID-19 pneumonia: lessons from bacterial pneumonia and sepsis. <i>European Respiratory Review</i> , 2020, 29, 200240.	3.0	16
690	Update on pharmacological treatment of acute coronary syndrome without persistent ST segment elevation myocardial infarction in the elderly. <i>Journal of Geriatric Cardiology</i> , 2017, 14, 457-464.	0.2	4
691	Synthesis of Indole Derived Protease-Activated Receptor 4 Antagonists and Characterization in Human Platelets. <i>PLoS ONE</i> , 2013, 8, e65528.	1.1	27
692	Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database. <i>PLoS ONE</i> , 2016, 11, e0150475.	1.1	12

#	ARTICLE	IF	CITATIONS
693	Humanizing the Protease-Activated Receptor (PAR) Expression Profile in Mouse Platelets by Knocking PAR1 into the Par3 Locus Reveals PAR1 Expression Is Not Tolerated in Mouse Platelets. PLoS ONE, 2016, 11, e0165565.	1.1	16
694	Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. PLoS ONE, 2017, 12, e0186961.	1.1	21
695	Optimum Utilisation of Novel Antiplatelet Agents in Clinical Practice. Interventional Cardiology Review, 2014, 9, 164.	0.7	1
696	Drugs targeting protease-activated receptor-4 improve the anti-thrombotic therapeutic window. Annals of Translational Medicine, 2017, 5, 464-464.	0.7	7
697	A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes. Current Pharmaceutical Design, 2019, 25, 4063-4084.	0.9	200
698	Antithrombotic Treatment in Diabetes Mellitus: A Review of the Literature about Antiplatelet and Anticoagulation Strategies Used for Diabetic Patients in Primary and Secondary Prevention. Current Pharmaceutical Design, 2020, 26, 2780-2788.	0.9	14
699	Antiplatelet agents in clinical practice and their haemorrhagic risk. Blood Transfusion, 2013, 11, 349-56.	0.3	20
700	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. Ecanermedicalsience, 2020, 14, 998.	0.6	4
701	Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction. Journal of Pharmacy and Bioallied Sciences, 2016, 8, 98.	0.2	4
702	Trials of antithrombotic therapy in percutaneous coronary intervention: what evidence do we need to optimise our practice?. EuroIntervention, 2018, 14, 19-23.	1.4	2
703	Platelet function, coagulation and fibrinolysis in patients with previous coronary and cerebrovascular ischemic events. Clinics, 2019, 74, e1222.	0.6	2
704	Ticagrelor-induced Diarrhea in a Patient with Acute Coronary Syndrome Requiring Percutaneous Coronary Artery Intervention. Cureus, 2019, 11, e3874.	0.2	6
705	The Evolving Concept of Neuro-Thromboinflammation for Neurodegenerative Disorders and Neurotrauma: A Rationale for PAR1-Targeting Therapies. Biomolecules, 2021, 11, 1558.	1.8	1
706	Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P&TIMI 50 Trial. Journal of the American Heart Association, 2021, 10, e021412.	1.6	1
707	No benefit of vorapaxar on walking performance in patients with intermittent claudication. Vascular Medicine, 2021, , 1358863X2110420.	0.8	0
708	Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The "Circulating Wound" Model. International Journal of Molecular Sciences, 2021, 22, 11343.	1.8	4
712	Agents antiplaquettaires et athr thrombose. Bulletin De L'Academie Nationale De Medecine, 2013, 197, 375-388.	0.0	0
714	Anticoagulation Therapy. Heparins, Factor II and Factor Xa Inhibitors. , 2014, , 59-122.		0

#	ARTICLE	IF	CITATIONS
715	Progress of antiplatelet therapy. Nosotchu, 2014, 36, 210-215.	0.0	0
716	Antiplatelet Drugs in the Management of Cardiovascular Indications. , 2014, , 1-24.		0
717	Monitoring Committee Structure and Function. , 2015, , 343-372.		0
718	Diplopia on vorapaxar: An unexpected side effect emerging only at second glance. Thrombosis and Haemostasis, 2016, 115, 911-912.	1.8	0
719	Blood thinners and gastrointestinal endoscopy. World Journal of Gastrointestinal Endoscopy, 2016, 8, 584.	0.4	1
720	Antiplatelet therapy in cardiology. Klinicheskaia Meditsina, 2016, 94, 729-735.	0.2	0
721	Platelets in Acute Coronary Syndromes. , 2017, , 1015-1028.		0
722	Modern principles of antiplatelet antithrombotic therapy. Klinicheskaia Meditsina, 2017, 95, 586-593.	0.2	0
723	Data Monitoring: Structure for Clinical Trials and Sequential Monitoring Procedures. ICSA Book Series in Statistics, 2018, , 235-267.	0.0	0
724	Antiplatelet Therapy in Cardiovascular Disease. , 2019, , 195-207.		0
726	A Vaccine for Ischemic Stroke. , 2019, , 21-32.		0
727	Risk Factors and Prevention in Light of Atherosclerosis Being a Microvascular Disease. , 2019, , 75-95.		0
730	The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease. Meditsinskiy Sovet, 2019, , 34-41.	0.1	0
731	Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition. Expert Review of Clinical Pharmacology, 2020, 13, 695-706.	1.3	4
732	Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events â€” A Review on Vorapaxar. Current Problems in Cardiology, 2023, 48, 101035.	1.1	4
733	Autoantibodies from Patients with Scleroderma Renal Crisis Promote PAR-1 Receptor Activation and IL-6 Production in Endothelial Cells. International Journal of Molecular Sciences, 2021, 22, 11793.	1.8	14
734	Antithrombotic therapy for chronic ischemic heart disease: how to balance risk and benefit in different categories of patients?. Atherothrombosis, 2020, , 76-94.	0.1	0
735	Personalized Therapy of Cardiovascular Disorders. , 2021, , 279-316.		0

#	ARTICLE	IF	CITATIONS
736	Pharmacological management of cerebral ischemia in the elderly. Expert Opinion on Pharmacotherapy, 2021, 22, 897-906.	0.9	4
737	Management of Processes of the Diagnosis and Treatment of Acute Myocardial Infarction Using Telematics Systems. Communications in Computer and Information Science, 2020, , 429-442.	0.4	1
738	Prospects of rivaroxaban application in treatment of patients with chronic ischemic heart disease. Meditsinskiy Sovet, 2020, , 44-50.	0.1	0
739	Platelets in the Pathogenesis of Vascular Disease and Their Role as a Therapeutic Target. , 2020, , 233-261.		0
741	Eligibility for extended antithrombotic therapy for secondary prevention of acute coronary syndrome. Revista Portuguesa De Cardiologia (English Edition), 2020, 39, 493-501.	0.2	0
742	Controversies in the use & implementation of drug-eluting stent technology. Indian Journal of Medical Research, 2012, 136, 926-41.	0.4	0
743	Development and course of heart failure after a myocardial infarction in younger and older people. Journal of Geriatric Cardiology, 2014, 11, 1-12.	0.2	31
744	Down-regulation of the clotting cascade by the protein C pathway. Hematology Education, 2013, 7, 365-374.	0.0	3
745	Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death. American Health and Drug Benefits, 2015, 8, 148-51.	0.5	24
746	ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy. European Heart Journal Supplements, 2017, 19, D163-D189.	0.0	0
747	Vorapaxar as an Alternative for Ticagrelor Resistance in Neuroendovascular Intervention. , 2021, 1, .		1
748	Net clinical benefit of antiplatelet therapy was affected by patient preferences: A personalized benefit-risk assessment. Journal of Clinical Epidemiology, 2022, 144, 84-92.	2.4	2
749	Regulation of Key Antiplatelet Pathways by Bioactive Compounds with Minimal Bleeding Risk. International Journal of Molecular Sciences, 2021, 22, 12380.	1.8	5
750	Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization. Atherosclerosis, 2021, 339, 12-19.	0.4	4
751	Protease-Activated Receptors (PARs). , 2021, , 1277-1288.		0
752	Evaluation of the Role of Antiplatelet Medications in Cardiovascular Disease. Pharmacophore, 2021, 12, 97-103.	0.2	3
753	Antiplatelet Therapy for Atherothrombotic Disease in 2022â€”From Population to Patient-Centered Approaches. Frontiers in Cardiovascular Medicine, 2022, 9, 805525.	1.1	12
754	A Review of Antithrombotic Therapies for Patients with Chronic Peripheral Arterial Disease and after Revascularization. Angiology, 2022, , 000331972110485.	0.8	0



#	ARTICLE	IF	CITATIONS
755	Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis. <i>Platelets</i> , 2022, 33, 879-886.	1.1	5
756	Protease Activated Receptors: A Pathway to Boosting Mesenchymal Stromal Cell Therapeutic Efficacy in Acute Respiratory Distress Syndrome?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1277.	1.8	0
757	Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13079.	1.8	20
760	Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies. <i>Journal of Tissue Engineering</i> , 2022, 13, 204173142210885.	2.3	7
761	Pregnancy-specific expression of protease-activated receptor 1: a therapeutic target for prevention and treatment of preeclampsia?. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, S945-S953.	0.7	7
762	Antiplatelet agents for chronic kidney disease. <i>The Cochrane Library</i> , 2022, 2022, CD008834.	1.5	6
763	State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1279-1287.	1.8	11
764	When and How to Combine Antiplatelet and Anticoagulant Drugs?. <i>Hamostaseologie</i> , 2022, 42, 073-079.	0.9	7
765	Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1193-1205.	1.9	3
766	An optimized agonist peptide of protease-activated receptor 4 and its use in a validated platelet-aggregation assay. <i>Platelets</i> , 2022, 33, 979-986.	1.1	3
767	Factors Associated with Platelet Activation-Recent Pharmaceutical Approaches. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3301.	1.8	7
768	Intracoronary Application of Super-Saturated Oxygen to Reduce Infarct Size Following Myocardial Infarction. <i>Journal of Clinical Medicine</i> , 2022, 11, 1509.	1.0	6
772	Protease-activated receptor antagonists prevent thrombosis when dual antiplatelet therapy is insufficient in an occlusive thrombosis microfluidic model. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12703.	1.0	2
774	Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines. <i>Frontiers in Pharmacology</i> , 2022, 13, 878416.	1.6	2
777	Protease-activated receptor 1 mediated altered Ca <sup>2+</sup> signaling in gliomas. <i>Journal of King Saud University - Science</i> , 2022, 34, 102039.	1.6	0
778	Platelet-to-Lymphocyte Ratio as Marker of Platelet Activation in Patients on Potent P2Y <sub>12</sub> Inhibitors. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022, 27, 107424842210965.	1.0	2
779	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. , 2013, , 332-397.		1
780	IUA position statement on perioperative drug and hemostasis management in vascular surgery. <i>International Angiology</i> , 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
781	Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. <i>JAMA Network Open</i> , 2022, 5, e2215580.	2.8	11
782	Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8843-8854.	2.9	14
783	Direct oral anticoagulants and peripheral arterial disease. , 2022, 1, 76-79.		0
784	New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans. <i>Platelets</i> , 2022, 33, 969-978.	1.1	7
785	Peripheral Artery Disease. , 2022, , 180-188.		0
786	Critical Limb Ischemia: Update for the Cardiovascular Anesthesiologist. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 3939-3944.	0.6	1
787	Management of Oral Anticoagulation and Antiplatelet Therapy in Post-Myocardial Infarction Patients with Acute Ischemic Stroke with and without Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2022, 11, 3894.	1.0	1
788	Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2Â°Pâ€¦TIMI 50 trial. <i>Clinical Cardiology</i> , 2022, 45, 831-838.	0.7	4
789	Protease-activated receptors in health and disease. <i>Physiological Reviews</i> , 2023, 103, 717-785.	13.1	21
790	Polypharmacology in Clinical Applications: Cardiovascular Polypharmacology. , 2022, , 133-198.		0
791	MicroRNA-375 repression of Kruppel-like factor 5 improves angiogenesis in diabetic critical limb ischemia. <i>Angiogenesis</i> , 2023, 26, 107-127.	3.7	9
792	A case history in natural product-based drug discovery: discovery of vorapaxar (Zontivityâ„¢). <i>Medicinal Chemistry Research</i> , 2022, 31, 1623-1636.	1.1	1
793	Hemostatic Effect of 20(S)-Panaxadiol by Induced Platelet Aggregation Depending on Calcium Signaling Pathway. <i>BioMed Research International</i> , 2022, 2022, 1-18.	0.9	1
794	Emerging roles of protease-activated receptors in cardiometabolic disorders. <i>Journal of Cardiology</i> , 2023, 81, 337-346.	0.8	2
795	Novel Therapeutic Strategies to Reduce Reperfusion Injury After Acute Myocardial Infarction. <i>Current Problems in Cardiology</i> , 2022, 47, 101398.	1.1	17
796	Antithrombotic therapy in peripheral arterial disease. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0
797	Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. , 2022, 1, 100513.		3
798	Discovery of four plasmatic biomarkers potentially predicting cardiovascular outcome in peripheral artery disease. <i>Scientific Reports</i> , 2022, 12, .	1.6	5

#	ARTICLE	IF	CITATIONS
799	Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19. <i>Thrombosis Update</i> , 2022, , 100126.	0.4	0
800	Anticoagulation and Antiplatelet Agents in Peripheral Arterial Interventions. <i>Seminars in Interventional Radiology</i> , 2022, 39, 364-372.	0.3	0
801	Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease: releasing the evidence vacuum. <i>Platelets</i> , 2023, 34, .	1.1	2
802	Antiplatelet Therapy in Coronary Artery Disease: Now and Then. <i>Seminars in Thrombosis and Hemostasis</i> , 0, , .	1.5	2
803	Oligosaccharide Blocks PAR1 (Proteinase-Activated Receptor 1)-PAR4-Mediated Platelet Activation by Binding to Thrombin Exosite II and Impairs Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2023, 43, 253-266.	1.1	1
804	The Effect of Protease-Activated Receptor-1 (PAR-1) Inhibition on Endothelial-Related Biomarkers in Patients with Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , 2023, 123, 510-521.	1.8	2
805	Organocatalytic enantioselective construction of bicyclic $\beta$ -butrolactones. <i>Chinese Chemical Letters</i> , 2023, 34, 108121.	4.8	0
806	Organocatalytic Asymmetric Michael Addition Reaction of Aldehydes with 2-Furanones: Experimental, Applications and DFT Studies. <i>Organic Chemistry Frontiers</i> , 0, , .	2.3	0
807	Elevated levels of soluble glycoprotein V - The plasma marker of platelet activation by thrombin in patients with early stage primary biliary cholangitis (PBC). <i>Advances in Medical Sciences</i> , 2023, 68, 71-78.	0.9	1
808	Protease-activated receptors and glycoprotein VI cooperatively drive the platelet component in thromboelastography. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 2236-2247.	1.9	1
809	Breast Cancer Management in Developing Countries. , 2023, , 1-20.		0
810	Current concepts and novel targets for antiplatelet therapy. <i>Nature Reviews Cardiology</i> , 2023, 20, 583-599.	6.1	7
811	Editor's Choice " European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. <i>European Journal of Vascular and Endovascular Surgery</i> , 2023, 65, 627-689.	0.8	29
812	Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. <i>Journal of Cardiovascular Development and Disease</i> , 2023, 10, 164.	0.8	6
815	Thromboinflammatory challenges in stroke pathophysiology. <i>Seminars in Immunopathology</i> , 2023, 45, 389-410.	2.8	3
817	Risikofaktoren und Prvention im Licht der Atherosklerose als Mikrozirkulationskrankheit. , 2023, , 81-102.		0
826	Beginning and Managing Underlying Comorbidities. , 2023, , 49-63.		0
829	Lipoprotein(a), platelet function and cardiovascular disease. <i>Nature Reviews Cardiology</i> , 0, , .	6.1	4

#	ARTICLE	IF	CITATIONS
834	General Considerations for Neurointerventional Procedures. Contemporary Medical Imaging, 2023, , 173-262.	0.3	0